The test menus for developed and developing countries may differ, depending on many factors, including the expected volume of testing, disease frequency and therapies available, clinical impact of the test, technical skill and equipment needed, cost, the patient population served, and whether alternative testing sites are available, and some of them may not be exactly known. We assessed test priorities in a developing country by making a broad range of tests available and then assessing which tests were actually used by the physicians in the country for the care of their patients. Methods: The Barnes-Jewish Hospital laboratory and Washington University Medical Center provided patients in the developing country of Eritrea access to the same tests as patients in St. Louis for all analytes that are stable at 4°C, the lowest temperature that could be used for shipping. Results: The use of the St. Louis laboratories increased steadily from 1998 to 2001. More than one-half of the physicians in Eritrea used the reference laboratories, with requests for thyroid function and female fertility representing 48 -71% of the test requests over the 4 years evaluated. The high degree of utilization for these test batteries was not predicted. Testing for thyroid function, female fertility, and lipid panels are now performed, or soon will be performed, in Eritrea based on the experience of the reference laboratory system. The reference laboratory system is continuing so that the test priorities of the country can be evaluated on an ongoing
Setting priorities for which tests a hospital clinical laboratory should perform involves consideration of the expected volume of testing, its clinical impact, the technical skill levels available, the equipment needed, cost benefits, and whether testing can be obtained elsewhere. Most clinical laboratory directors in the US and other developed countries can obtain the above information via the medical literature, fellow laboratorians, specialist colleagues, sales representatives, and reference laboratories. In developing countries, such information may not be readily available and alternative testing sites, such as reference laboratories, may not be available. Here, we relate our experience in acting as a reference laboratory for the country of Eritrea and how this has been used to help set clinical laboratory priorities in Eritrea.
Eritrea is situated on the horn of Africa bordering Sudan, Ethiopia, and Djibouti. Its population is currently ϳ3.5 million. Hominid fossils dating to ϳ2 million years ago have been found in Southern Eritrea, and human settlement has been dated to 8000 BC. It was part of the Aksumite empire, which dates from around the first century AD. Christianity was established in the area by the fourth century AD and Islam in the seventh century, particularly in the coastal regions of the Red Sea. In more recent times, it was an Italian colony from 1890 until 1941. The United Nations federated Eritrea with Ethiopia in 1950, but Haile Sellassie, emperor of Ethiopia, annexed Eritrea in 1962, which started a movement for independence that was finally successful in 1991 (1 ) . The country of Eritrea was recognized by the United Nations in 1993.
During the war for independence, surprisingly effec-tive medical systems were devised and a small core of medical personnel was developed, including medical technicians, most of whom were high school graduates trained in the field. The organization of medical services after independence was planned to consist of a reference hospital, regional hospitals, health centers within each region, and health stations and clinics that would be the primary care contact for people in the villages. A central health laboratory would help coordinate and standardize the clinical laboratory work needed at the various levels of care and also act as a reference and public health laboratory for the country. In 1994, Pathologists Overseas, Inc., became involved in aiding the Ministry of Health and the Central Health Laboratory (CHL). 4 Pathologists Overseas was founded in 1990 by Heinz Hoenecke to help improve and provide affordable pathology services to underserved patients worldwide. This is accomplished through volunteer efforts of pathologists, clinical laboratory scientists, and medical technologists.
The broad objectives of the current project in Eritrea are to (a) upgrade and standardize laboratory practices and procedures, (b) introduce appropriate new technologies, (c) provide advanced training and continuing education for laboratory personnel, and (d) train an Eritrean medical practitioner in clinical and anatomic pathology.
The purpose of this report is to relate our experience in using a major medical center in the US as a reference laboratory for a developing country to both extend "specialized" testing to patients with no other access and to utilize the information gained as a priority-setting tool for laboratory tests to be made available within the country to best utilize the limited resources available.
Materials and Methods policy for performing tests
Any tests that were available to patients at Barnes-Jewish Hospital were made available to patients in Eritrea if sample stability permitted.
For tests that were not performed for patients at Barnes-Jewish Hospital without approval by the on-call resident or fellow, we used consultation via e-mail or fax. The approval system at Barnes-Jewish Hospital includes very expensive tests, tests often misinterpreted, or tests that have value only in a highly selected group of patients. The communications were often prolonged, as there was no e-mail during the time of this study in any of the hospitals in Eritrea and communication had to be via a supervisor or volunteer in the CHL. Thus, we discouraged drawing any samples that needed approval until after consultation.
sample stability
Attempts to make dry ice in Eritrea only achieved a density suitable for ϳ6 h, which was not sufficient to reach St. Louis. Therefore, samples that required freezing could not be analyzed. Whole blood samples were also problematic because we found that samples often froze in the cargo compartments of the airplanes in which they were shipped, thus lysing the cells.
The stability of the analytes that would be measured at Barnes-Jewish Hospital was assessed by literature, reference laboratory sources, and our own internal stability data, assuming storage conditions of 4°C. For some analytes we confirmed stability as follows:
Three serum or plasma samples and their corresponding quality-control materials, representing a range of values, were analyzed in St. Louis and then sent to Asmara, the capital of Eritrea, on cold packs via Federal Express. On arrival in Asmara, the samples were taken to the CHL, where they were placed in the refrigerator and then later repacked on cold packs and sent back to St. Louis. The samples were ϳ48 h in transit from Asmara to St. Louis. Total time from date of sending samples from St. Louis to receiving them back in St. Louis was 11-22 days. On arrival in St. Louis, the samples were reanalyzed. Samples were judged clinically stable if the values obtained after the samples were returned from Asmara were within the Healthcare Financing Administration (HCFA)/CLIA criteria for acceptable performance compared with the value obtained in St. Louis before the sample was shipped to Asmara (2 ). For samples without absolute performance HCFA/CLIA criteria, the most recent College of American Pathologists report was consulted to obtain the SD range for each test (2 ) . Analytes were considered acceptably stable if repeat results were within 3 SD of the initial results. Quality-control samples were also examined to determine whether the value on the returned quality-control sample was within our acceptable range (within 2 SD of the mean value). Analytes that were examined in this fashion included components of the basic and complete metabolic panel, ␣-fetoprotein, carcinoembryonic antigen, cortisol, free thyroxine (T 4 ), folate, follicle-stimulating hormone (FSH), human chorionic gonadotropin, iron, HDL-cholesterol, luteinizing hormone, prolactin, prostate-specific antigen, thyroxine, troponin I, progesterone, thyroid-stimulating hormone (TSH), vitamin B 12 , and the therapeutic drugs carbamazepine, digoxin, gentamicin, phenobarbital, theophylline, and valproate.
The system for obtaining patient samples in Eritrea consisted of obtaining the appropriate sample in a regional hospital or in the outpatient collection area of the CHL. This was done by laboratory technicians, using Vacutainer Tubes, needles, and other blood-collection supplies, with techniques very similar to sample collection at Barnes-Jewish Hospital. The samples were centrifuged at the regional hospital or CHL and then refrigerated. A courier system brought samples from regional hospitals to the CHL, where all samples were prepared for shipping on the afternoon of the night that the plane was leaving Asmara. Generally, samples were obtained from the patient within 1 day before they were shipped, were in St. Louis within 48 h, and were assayed and the results faxed to Eritrea, where they were entered into their Polytech Laboratory Information System. Use of e-mail is much cheaper but had a high failure rate. Units and reference intervals were those in use at Barnes-Jewish Hospital.
Results
On return to St. Louis from Asmara, all patient samples (three for each analyte) produced repeat values that were within the HCFA/CLIA acceptable performance criteria with the exception of phenobarbital. For phenobarbital, two samples produced values 22% lower than the original value (HCFA criterion is Ϯ 20%); however, one other sample showed no decrease and the phenobarbital quality-control samples produced acceptable values. We therefore felt that it was practical to use the Barnes-Jewish Hospital laboratories as a reference laboratory for the country of Eritrea for the analytes whose stability we tested as well as other analytes for which stability at 4°C was known.
The volume of testing for Eritrea at Barnes-Jewish Hospital, 1998 -2001, is shown in Table 1 . The number of patients served increased steadily from 212 in 1998 to 2322 in 2001. Most of the samples came from government health facilities; only a few came from private patients. A canvas in 1999 indicated that almost one-half the ϳ120 physicians in the country, almost all of whom speak and understand English, had ordered testing that was performed by the Barnes-Jewish Hospital/Washington University reference laboratory. Note that some of the testorders were for batteries that included multiple tests, e.g., thyroid (TSH, T 4 , and T uptake) and female fertility (estradiol, FSH, luteinizing hormone, prolactin, and progesterone). These two test batteries accounted for 48 -71% of the test requests. In keeping with the goals of this study, a few of the tests with higher volumes of requests are now performed in the CHL. T 4 and T uptake are performed at the CHL via a donated Hitachi 717 analyzer, with 1847 of each test performed in Asmara in 2001. TSH is sent to St. Louis only when the free T 4 index is abnormal or when anomalies are present in the laboratory data or patient presentation. Although this is somewhat reversed from current recommendations (3 ), it is a practical strategy that helps conserve resources, uses the equipment available in the CHL (Hitachi 717), and was readily accepted by the physicians in Eritrea. Lipid panel testing is also now performed at CHL with 1280 panels performed in 2001. Immunoassay equipment for performing fertility and TSH testing has been obtained, and these tests should be available in Eritrea sometime in 2003.
The percentages of abnormal values for selected tests are shown in Table 2 . It is difficult to assess the number of abnormal tests for the female fertility work-up because we often did not have information about such variables as age and stage of ovulation cycle. For thyroid function, the percentage of abnormal tests was 55% in 2001 and near 40% in the previous years. This is vastly greater than we experience for the other patients we test at Barnes-Jewish Hospital laboratories (10 -15%), suggesting appropriate preselection of patients by Eritrean physicians based on clinical presentation. The relatively high amount of hy- perthyroidism could be related to the introduction of iodide into salt in 1997, a phenomenon well documented to increase hyperthyroidism when iodine supplementation is introduced into an iodine-deficient country (4 ) . In 1998, we extended the reference laboratory work to include hematopathology, consisting generally of a bone marrow aspirate and a peripheral blood smear. Although the hematology section of the CHL could often make a preliminary diagnosis, there have been prolonged periods without any surgical pathologist or other individual with hematopathology experience, so this reference hematopathology service has been used to provide definitive diagnoses. The experience with the hematopathology samples is shown in Table 3 .
Discussion
The criteria for setting priorities for testing in a clinical laboratory in a developing country are not substantially different from those in the US. There must be assessments of medical need, cost, complexity of testing, physician and patient preferences, and other factors that are difficult to quantify. Moreover, the priorities given to these different factors obviously can be quite different in a developing country.
In the Washington University Medical Center, decisions concerning which tests to perform in the hospital laboratory are made by a committee that includes clinicians, laboratorians, and administrators. Although this group makes decisions about which tests are actually performed in the Barnes-Jewish Hospital laboratories, many other tests are sent to reference laboratories.
The situation in Eritrea, as in other poor developing countries, can be quite different, mainly because of the decreased resources available. The health services provided by the government form a spectrum from hospitals to health stations. The health station is the smallest health unit in the health service structure and serves a population of ϳ10 000. It is staffed by a registered nurse and one or two associate nurse/health assistant(s). An associate nurse/health assistant is trained for 1 year past high school. The leading causes of morbidity are upper respiratory tract infections, diarrhea, malaria, tuberculosis, HIV/AIDS, anemia, and malnutrition.
By necessity, therapeutic and diagnostic priorities must address these diseases, and the drugs available in government health facilities are generally first-or second-generation, generic drugs. Patients needing other medications or therapeutic procedures must seek them out of country. Moreover, the public health testing functions in the US generally performed by state public health laboratories or the CDC (e.g., water quality, food quality, support of epidemiology studies) are part of the mandate of the CHL in Eritrea, as they are in many developing countries. Against this background, the choice of clinical laboratory tests to be performed needs to be carefully chosen, given the finite resources available.
Basic laboratory services in direct support of identification of the major infectious diseases are present to various extents in most developing countries, as they are in Eritrea. The chronic diseases that occur in the developed world also occur in the developing world, and the death rate from noncommunicable diseases of individuals who survive childhood is not that dramatically different around the world (5 ) .
There are several ways priorities can be set for diagnostic services. When we started to look at expansion of laboratory services, two of us (M.S. and J.H.L.) met with clinicians on two occasions in 1997. The list of "needed" procedures was essentially a list of available procedures in major medical centers in developed countries. The number of "essential" procedures seemed to correlate with the number of physicians at the meeting. This is not a reflection on the competence of the medical practitioners, but we feel it indicates that they were cognizant of the medical literature but had little actual experience with the array of diagnostic procedures they read about.
After much discussion with various individuals in the Ministry of Health, Pathologists Overseas, and Washington University Medical Center, we decided to use the Washington University Medical Center as a reference laboratory for the country of Eritrea. Periodically, a Pathologist Overseas volunteer would go to Eritrea to help educate the clinicians about some of the laboratory tests. For example, this was done when the thyroid and fertility batteries were being assembled. We felt that the reference laboratory would allow familiarization with laboratory tests, enhance the diagnostic capabilities for the country, and allow a realistic priority list to be developed. This would allow available internal resources in Eritrea to be used to strengthen basic laboratory services, such as routine clinical chemistry and hematology, and their quality assurance (6, 7 ) . The importance of using internal resources for the actual health problems of the country and not just using systems more suitable for a developed country's health problems has been emphasized by others (8 ); we all wanted to avoid the latter in Eritrea.
We feel that these goals were achieved. Thyroid function testing (T 4 and T uptake) are now performed in the country and means for performing TSH measurements and tests related to female fertility are being obtained. We chose to measure T 4 and T uptake rather than free T 4 when we started the reference system in 1997, as these were the tests primarily used at Barnes-Jewish Hospital at the time. We later elected not to shift to free T 4 because the capability to perform T 4 and T uptake on a donated Hitachi 717 was available in the country. Likewise, lipid testing is now available in Eritrea. Quality assurance for these tests (and others already performed in Eritrea) is enhanced by periodic patient samples and quality-control materials sent from St. Louis. The recent increase in serology requests has prompted discussion of performing prevalence testing for exposure to a variety of pathogens, both to better interpret data for individual patients and to help set health priorities for the country.
The cost of the reference laboratory program has been approximately US $60 000/year, which includes the actual test costs (not charges) at Barnes-Jewish Hospital (ϳ$50 000) and the shipping, faxing, and associated costs (ϳ$10 000). We believe this to be a bargain for providing access to diagnostic laboratory tests for a population of ϳ3 million people. We believe that many medical centers could easily support such efforts once the logistics are set up. In some larger countries, regional rather than national systems may be necessary, but if a good logistical system and a coordinated laboratory test system can be set up, then we believe our experience can be repeated.
A possible criticism of access to "advanced" laboratory tests is the feeling of futility that could occur when the diagnosed condition is not treatable in the country. We believe it is far worse to divert money for equipment, reagents, and personnel for medical systems that are not appropriate for most patients in the country (6, 8, 9 ) . It has been our experience that individuals have sometimes sought treatment outside the country, generally via relatives in the worldwide network of ex-patriot Eritreans. In addition, some patients are treated via donation of medical therapy by health facilities outside the country. For example, many of the children with leukemia have been treated without charge in Germany. Even when this does not occur, many patients have expressed gratitude for knowing what was wrong with them so that they, and their extended families, could prepare for the future.
In summary, we believe that access to clinical laboratory testing via a remote medical center can facilitate estimation of actual testing needs in a developing country and can itself be a useful service. We believe that our experiences in Eritrea can be utilized for similar programs in other developing countries.
